Exabis Library
Welcome to the e-CCO Library!
DOP19: Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP19: Myeloid and lymphoid cell abnormalities persist in the intestinal mucosa of patients who recover from COVID-19 infection
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP19: Real-world healthcare resource utilisation among patients with Inflammatory Bowel Disease administered vedolizumab for 6 months
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP19: Real-world healthcare resource utilisation among patients with Inflammatory Bowel Disease administered vedolizumab for 6 months
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP19: Spermidine treatment ameliorates experimental colitis in vivo
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP19: Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP20: Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP20: Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP20: Changes in systemic antibody epitope repertoires from preclinical to established Inflammatory Bowel Disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP20: Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP20: Drugs that modulate histone acetylation disrupt TGF-β- signalling and reduce collagen I expression in models of stricturing Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP20: Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP20: Genetic of vitamin D as predictor of response to adalimumab in Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP20: The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 – 2018
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP20: The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 – 2018
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP21: Disease activity patterns of paediatric Inflammatory Bowel Disease – A Danish nationwide cohort study 1996-2018
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP21: Disease activity patterns of paediatric Inflammatory Bowel Disease – A Danish nationwide cohort study 1996-2018
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP21: Histo-endoscopic remission (HEMR) Predicts Future Relapse in Patients with Ulcerative Colitis and is Associated with Lower Colectomy Risk
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM